Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple blood test could spare thousands from unnecessary chemo

NCT ID NCT06076811

Knowledge-focused Sponsor: University of Aarhus Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether a blood test for tumor DNA can better predict if colorectal cancer will come back after surgery. Currently, doctors use tumor tissue to decide who needs chemotherapy, but many patients get chemo they may not need. The test checks for cancer DNA in the blood, which could be a more accurate way to find hidden cancer cells. Researchers will follow 1,600 patients to see if the test works in real-world practice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
liquid biopsy (circulating tumor DNA test)
What this could lead to
If successful, this blood test could become a standard way to identify which colorectal cancer patients need chemotherapy after surgery, sparing others from unnecessary side effects.
What could go wrong
This is an observational study, not a treatment trial. The test may not prove more accurate than current methods, and results may not change practice immediately.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2023

Expected to finish

Jul 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

DANISH.MRD part I - Surgery Patients with colorectal cancer clinical stage I-III scheduled for curative-intent resectional surgery. DANISH.MRD part I - Surveillance Patients participating in DANISH.MRD part 1, and pathological stage III colorectal cancer, and candidates for adjuvant chemotherapy.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

DANISH.MRD part I - Surgery Inclusion Criteria: * Colon or rectal cancer, clinical tumor stage I-III. * Patient able to understand and sign written informed consent. * Scheduled for curative-intent resectional surgery (including "compromised" curative resections). Exclusion Criteria: * Hereditary colorectal cancer linked to familial colonic polyposis or Lynch syndrome. * Inflammatory bowel disease (Crohn's disease or ulcerative colitis). * Verified distant metastases. * Malignant colorectal polyps diagnosed after polypectomy. * Patients who are unlikely to comply with the protocol (e.g., uncooperative attitude, inability to return for subsequent visits) and/or otherwise considered by the Investigator to be unlikely to complete the study. DANISH.MRD part II - Surveillance Inclusion Criteria: * Participation in DANISH.MRD part I - Surgery. * Colorectal cancer, UICC stage III. * Has received curative-intent resection and is a candidate for adjuvant chemotherapy (3- or 6-months regime). Exclusion Criteria: * Not treated with adjuvant chemotherapy * Treated with neoadjuvant chemo-radiation therapy. * Synchronous colorectal and non-colorectal cancer diagnosed per operative (except skin cancer other than melanoma). * Other cancers (excluding colorectal cancer or skin cancer other than melanoma) within 3 years from eligibility screening. * Patients who are unlikely to comply with the protocol (e.g., uncooperative attitude, inability to return for subsequent visits) and/or otherwise considered by the Investigator to be unlikely to complete the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma colorectal cancer colorectal carcinoma colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal adenocarcinoma Colorectal cancer Colorectal cancer stage I Colorectal cancer stage II Colorectal cancer stage III Colorectal neoplasms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aalborg University Hospital

    RECRUITING

    Aalborg, North Denmark, 9000, Denmark

  • Aarhus University Hospital

    RECRUITING

    Aarhus, Central Jutland, 8000, Denmark

  • Bispebjerg Hospital

    RECRUITING

    Copenhagen, Capital Region of Denmark, 2400, Denmark

  • Gødstrup Hospital

    RECRUITING

    Herning, Central Jutland, 7400, Denmark

  • Herlev Hospital

    NOT_YET_RECRUITING

    Herlev, Capital Region of Denmark, 2730, Denmark

  • Odense University Hospital

    RECRUITING

    Odense, The Region of Southern Denmark, 5000, Denmark

  • Regional Hospital Horsens

    RECRUITING

    Horsens, Central Jutland, 8700, Denmark

  • Regional Hospital Randers

    RECRUITING

    Randers, Central Jutland, 8930, Denmark

  • Regional Hospital Viborg

    RECRUITING

    Viborg, Central Jutland, 8800, Denmark

  • Vejle Hospital

    RECRUITING

    Vejle, 7100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.